News Release Details
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
Participants may access a live webcast of the event through the following link: https://journey.ct.events/view/f4644667-cfc0-4e04-9eea-ad7eb829da8e.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum contagiosum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Financial Officer
Source: Verrica Pharmaceuticals Inc.